496 related articles for article (PubMed ID: 20614439)
41. Mycoplasma pneumoniae and community-acquired pneumonia.
Dey AB; Chaudhry R; Kumar P; Nisar N; Nagarkar KM
Natl Med J India; 2000; 13(2):66-70. PubMed ID: 10835852
[TBL] [Abstract][Full Text] [Related]
42. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients.
Kawai Y; Miyashita N; Yamaguchi T; Saitoh A; Kondoh E; Fujimoto H; Teranishi H; Inoue M; Wakabayashi T; Akaike H; Ogita S; Kawasaki K; Terada K; Kishi F; Ouchi K
Respirology; 2012 Feb; 17(2):354-62. PubMed ID: 22077195
[TBL] [Abstract][Full Text] [Related]
43. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.
Schuetz P; Müller B; Christ-Crain M; Stolz D; Tamm M; Bouadma L; Luyt CE; Wolff M; Chastre J; Tubach F; Kristoffersen KB; Burkhardt O; Welte T; Schroeder S; Nobre V; Wei L; Bhatnagar N; Bucher HC; Briel M
Evid Based Child Health; 2013 Jul; 8(4):1297-371. PubMed ID: 23877944
[TBL] [Abstract][Full Text] [Related]
44. Macrolide prescription in Dutch children: compliance with guidelines.
Bandell RAM; Dekkers T; Semmekrot BA; de Wildt SN; Fleuren HWHA; Warlé-van Herwaarden MF; Füssenich P; Gerrits GP; Kramers C
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):675-681. PubMed ID: 30680574
[TBL] [Abstract][Full Text] [Related]
45. Mycoplasma pneumoniae detection in children with respiratory tract infections and influence on management - a retrospective cohort study in Switzerland.
Dierig A; Hirsch HH; Decker ML; Bielicki JA; Heininger U; Ritz N
Acta Paediatr; 2020 Feb; 109(2):375-380. PubMed ID: 31168877
[TBL] [Abstract][Full Text] [Related]
46. Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae.
Isozumi R; Yoshimine H; Morozumi M; Ubukata K; Ariyoshi K
Respirology; 2009 Nov; 14(8):1206-8. PubMed ID: 19732389
[TBL] [Abstract][Full Text] [Related]
47. Mycoplasma pneumoniae P1 Genotype Indicates Severity of Lower Respiratory Tract Infections in Children.
Rodman Berlot J; Krivec U; Mrvič T; Kogoj R; Keše D
J Clin Microbiol; 2021 Jul; 59(8):e0022021. PubMed ID: 33980654
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.
Harris JA; Kolokathis A; Campbell M; Cassell GH; Hammerschlag MR
Pediatr Infect Dis J; 1998 Oct; 17(10):865-71. PubMed ID: 9802626
[TBL] [Abstract][Full Text] [Related]
49. Delayed antibiotics for symptoms and complications of respiratory infections.
Spurling GK; Del Mar CB; Dooley L; Foxlee R
Cochrane Database Syst Rev; 2004 Oct; (4):CD004417. PubMed ID: 15495108
[TBL] [Abstract][Full Text] [Related]
50. A comparative study of general and severe mycoplasma pneumoniae pneumonia in children.
Yang S; Lu S; Guo Y; Luan W; Liu J; Wang L
BMC Infect Dis; 2024 Apr; 24(1):449. PubMed ID: 38671341
[TBL] [Abstract][Full Text] [Related]
51. Comparison of PCR, culture & serological tests for the diagnosis of Mycoplasma pneumoniae in community-acquired lower respiratory tract infections in children.
Kashyap B; Kumar S; Sethi GR; Das BC; Saigal SR
Indian J Med Res; 2008 Aug; 128(2):134-9. PubMed ID: 19001676
[TBL] [Abstract][Full Text] [Related]
52. Mycoplasma pneumonia in young children, 2-5 years of age.
Bunnag T; Lochindarat S; Srisan P; Jetanachai P
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S124-7. PubMed ID: 19253507
[TBL] [Abstract][Full Text] [Related]
53. Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland.
Meyer Sauteur PM; Bleisch B; Voit A; Maurer FP; Relly C; Berger C; Nadal D; Bloemberg GV
Swiss Med Wkly; 2014; 144():w14041. PubMed ID: 25254315
[No Abstract] [Full Text] [Related]
54. Macrolide use shortens fever duration in Mycoplasma pneumoniae infection in children: a 2-year experience.
Lu YJ; Chen TH; Lin LH; Shen CM; Huang CH
J Microbiol Immunol Infect; 2008 Aug; 41(4):307-10. PubMed ID: 18787737
[TBL] [Abstract][Full Text] [Related]
55. Transmission of macrolide-resistant Mycoplasma pneumoniae within a family.
Miyashita N; Kawai Y; Akaike H; Teranishi H; Ouchi K; Okimoto N
J Infect Chemother; 2013 Dec; 19(6):1196-201. PubMed ID: 23624834
[TBL] [Abstract][Full Text] [Related]
56. Clinical characteristics of patients with Mycoplasma pneumoniae infection.
Álvaro Varela AI; Aguinaga Pérez A; Navascués Ortega A; Castilla J; Ezpeleta Baquedano C
Enferm Infecc Microbiol Clin (Engl Ed); 2022 Oct; 40(8):449-452. PubMed ID: 36154990
[TBL] [Abstract][Full Text] [Related]
57. Beta2-agonists for acute bronchitis.
Becker LA; Hom J; Villasis-Keever M; van der Wouden JC
Cochrane Database Syst Rev; 2011 Jul; (7):CD001726. PubMed ID: 21735384
[TBL] [Abstract][Full Text] [Related]
58. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children.
Tsai TA; Tsai CK; Kuo KC; Yu HR
J Microbiol Immunol Infect; 2021 Aug; 54(4):557-565. PubMed ID: 33268306
[TBL] [Abstract][Full Text] [Related]
59. The epidemiology, clinical characteristics, and macrolide susceptibility of Mycoplasma pneumoniae pneumonia in children in Southern Taiwan, 2019-2020.
Kuo CY; Tsai WC; Lee HF; Ho TS; Huang LM; Shen CF; Liu CC;
J Microbiol Immunol Infect; 2022 Aug; 55(4):611-619. PubMed ID: 34688576
[TBL] [Abstract][Full Text] [Related]
60. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Herath SC; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
